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The purpose of this study was to evaluate the therapeutic options for diabetes treatment and their potential side
effects, in addition to analyzing the risks and benefits of tight glycemic control in patients with diabetic kidney
disease. For this review, a search was performed using several pre-defined keyword combinations and their
equivalents: ‘‘diabetes kidney disease’’ and ‘‘renal failure’’ in combination with ‘‘diabetes treatment’’ and ‘‘oral
antidiabetic drugs’’ or ‘‘oral hypoglycemic agents.’’ The search was performed in PubMed, Endocrine Abstracts and
the Cochrane Library from January 1980 up to January 2015. Diabetes treatment in patients with diabetic kidney
disease is challenging, in part because of progression of renal failure-related changes in insulin signaling, glucose
transport and metabolism, favoring both hyperglycemic peaks and hypoglycemia. Additionally, the decline in renal
function impairs the clearance and metabolism of antidiabetic agents and insulin, frequently requiring reassessment
of prescriptions. The management of hyperglycemia in patients with diabetic kidney disease is even more difficult,
requiring adjustment of antidiabetic agents and insulin doses. The health team responsible for the follow-up of
these patients should be vigilant and prepared to make such changes; however, unfortunately, there are few
guidelines addressing the nuances of the management of this specific population.
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Diabetes mellitus is the leading cause of chronic kidney
disease (CKD) and a major public health issue worldwide.
Approximately 20–30% of patients with type 2 diabetes mellitus
(T2DM) have renal impairment, classified as moderate-to-severe
CKD (glomerular filtration rate (GFR) o60mL/min/1.73m2)
(1). Unfortunately, the combination of diabetes and CKD is
associated with increased morbidity and mortality, mainly
due to increased cardiovascular risk (2).
Glycemic control in patients with kidney failure faces special
challenges. According to the progression of CKD, changes in
insulin signaling, glucose transport and metabolism are
associated with accumulation of uremic toxins, inflammatory
factors and oxidative stress, inducing insulin resistance and the
response of target tissues to insulin signaling (3-5).
The management of hyperglycemia in patients with CKD
is especially difficult, in part because of the treatment
complexity and in part due to insufficient convincing data
supporting the benefits of tight glycemic control in this
subset of patients. Furthermore, inherent risks, including
severe hypoglycemia and increased cardiovascular risk,
should be considered when formulating therapeutic strate-
gies (6-8).
The aim of this review article was to evaluate the
therapeutic options for diabetes treatment and their potential
side effects, in addition to analyzing the risks and benefits of
tight glycemic control in patients with diabetic kidney
disease (DKD).
For this review, a search was performed using several pre-
defined keyword combinations and their equivalents: ‘‘diabetes
kidney disease’’ and ‘‘renal failure’’ in combination with
‘‘diabetes treatment’’ and ‘‘oral antidiabetic drugs’’ (OADs) or
‘‘oral hypoglycemic agents.’’ The search was performed inDOI: 10.6061/clinics/2016(01)08
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PubMed, Endocrine Abstracts and the Cochrane Library from
January 1980 up to January 2015. Only full-text manuscripts
published in English were included in the study.
Antidiabetes therapy: Current options
Traditionally, insulin has been considered the safe choice for
treating diabetic patients with kidney injury. Recently, new oral
drug options have become good potential alternatives and
traditional medications used in diabetes treatment have had
their prescriptions and dosages reviewed.
Biguanide - Metformin
Usually, metformin is the initial pharmacological agent for
type 2 diabetes treatment (8). This drug acts mainly by
decreasing hepatic glucose production, increasing peripheral
glucose uptake, improving glucose tolerance and lowering
fasting and postprandial plasma glucose. The prescription of
metformin is contraindicated in DKD because it undergoes
renal excretion (9) and its most serious adverse effect is the
development of lactic acidosis, although this is a very rare
occurrence, with approximately 5 cases per 100,000 patient-
years (9). A current United Kingdom (UK) guideline on the
treatment of T2DM allows metformin use up to a GFR of
30 mL/min/1.73 m2, with dose reduction advised at
45 mL/min/1.73 m2 (10,11). In the USA, metformin is
contraindicated for men with serum creatinine X1.5 mg/dL
and for women with serum creatinine X1.4 mg/dL (8-12).
New evidence from the literature suggests that patients with
mild-to-moderate DKD face more benefits than risks while
using metformin (13-15). In fact, the REduction of Athero-
thrombosis for Continued Health (REACH) Registry 2004
showed decreased mortality associated with metformin use,
even in patients with moderate kidney disease (16,17).
Nonetheless, the use of metformin is still avoided in patients
with CKD stages 3–5 with other associated risk factors for
lactic acidosis. However, in recent years, studies based on
experimental and cell culture models have shown a potential
renal protective effect for metformin. In these studies,
metformin prevented glucose-induced oxidative stress in
podocytes by inhibiting NAD(P)H oxidase; decreasing
8-hydroxydeoxyguanosine (8-OHdG), a supposed marker
of total systemic oxidative stress and DNA damage in vivo;
and also improving the free-radical defense system (18-20).
Sulfonylureas
Sulfonylureas (SUs) are drugs that stimulate endogenous
insulin secretion by pancreatic b cells. These drugs may
potentially cause hypoglycemia, especially in association with
high doses; omission or reduction of carbohydrate intake;
alcohol abuse; hepatic dysfunction; heart failure; malnutrition;
advanced age; and interactions with certain drugs that
displace SUs from their plasma protein-binding sites (21)
because one or more of their metabolites may accumulate,
resulting in an increased risk of hypoglycemia (7). Several
drugs are included in this class. Glipizide is metabolized by
the liver into several inactive metabolites and its clearance and
elimination half-life are not affected by a reduction in the
estimated GFR (eGFR), so dose adjustments are not necessary
in patients with CKD (22). Therefore, glipizide is the SU of
choice in patients with CKD. Glibenclamide and glyburide are
each metabolized by the liver and are eliminated equally in
the bile and urine. Hypoglycemic episodes may be severe in
patients with renal failure, and the drugs are contraindicated
from stage 3 of CKD (eGFR o60 mL/min). Meanwhile,
glimepiride is metabolized by the liver into two main
metabolites, one of which has hypoglycemic activity. In
patients with renal impairment, these metabolites can
accumulate. Nevertheless, glimepiride is associated with less
hypoglycemia compared with glyburide, although its use
should be avoided in patients with a GFR of o60 mL/min
(23). Finally, gliclazide has inactive metabolites that are
eliminated mainly in the urine (80%) and presents a lower
risk of severe hypoglycemia than glibenclamide and glimepir-
ide do. This drug can be considered in renal impairment if
appropriate attention is paid to the dose. However, use should
be avoided if the GFR falls to o40 mL/min (7,21).
Glinides
Both repaglinide and nateglinide belong to a class of glinides,
which are Su-like agents that stimulate insulin secretion but are
rapidly absorbed, with a short duration of action, thus
contributing to reducing postprandial hyperglycemia. Nategli-
nide (but not repaglinide) is hepatically metabolized, with renal
excretion of active metabolites that are retained in DKD, so it
should be used with caution in patients with advanced renal
injury (24). In contrast, repaglinide is considered a safe option
until the GFR falls to o30 mL/min/1.73 m2 (25,26). In
advanced renal disease, treatment with repaglinide should
begin cautiously, with 0.5 mg daily, to avoid hypoglycemia.
Alpha-glucosidase inhibitors
Alpha-glucosidase inhibitors reduce the rate of digestion
and intestinal absorption of carbohydrates, resulting in mild
reduction of glycated hemoglobin (A1C). Acarbose is
metabolized nearly completely within the gastrointestinal
tract, so less than 2% of an oral dose is recovered as the active
drug or its metabolites in the urine. The other drug in this
class, or miglitol, is absorbed systemically and excreted
unchanged in the urine. Given their modest efficacy in
glycemic control and the lack of long-term trials in patients
with kidney disease, these medications should be avoided in
CKD stages 4 and 5 (27,28).
Glitazones
Pioglitazone is a thiazolidinedione (TZD) antidiabetic agent
that is a potent and highly selective agonist of peroxisome
proliferator-activated receptor-gamma (PPARg). PPAR recep-
tors are found in tissues important for insulin action, such as
the adipose tissue, skeletal muscle, and liver. Activation of
PPARg nuclear receptors modulates the transcription of a
number of insulin-responsive genes involved in the control of
glucose and lipid metabolism. The pharmacokinetic profile of
pioglitazone was found to be similar between healthy subjects
and patients with moderately or severely impaired renal
function who did not require dialysis (29). Post hoc analysis
from the PROspective pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) identified a greater decline in the
eGFR with pioglitazone (between-group difference of 0.8 mL/
min per 1.73 m(2)/yr) than with placebo (30). However, these
medications may cause fluid retention and thus should be used
with caution in patients with heart failure (HF) as well as in
those with CKD and a significant decrease in the GFR (28).
Dipeptidyl peptidase-4 inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation
of incretin hormones by DPP-4, enhancing glucose-dependent
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insulin secretion. There are five available DPP-4 inhibitors,
also known as ‘‘gliptins’’ (sitagliptin, vildagliptin, saxaglip-
tin, linagliptin and alogliptin), and despite their common
mechanism of action, these agents have structural hetero-
geneity that translates into different pharmacological proper-
ties and different metabolism and excretion pathways (31).
Sitagliptin is mostly eliminated unchanged in the urine and
can be used with appropriate dose reduction in all chronic
kidney stages. The usual dose of 100 mg once per day should
be adjusted to 50 mg/day for patients with moderate renal
impairment. In severe renal impairment (creatinine clearance
o30 mL/min) or end-stage renal disease (ESRD) requiring
dialysis, the dose is further reduced to 25 mg once daily (32).
Vildagliptin is metabolized, mostly in the kidneys, into
inactive metabolites. Its main route of elimination is hydro-
lysis by multiple tissues or organs and approximately 25%
of the drug is excreted unchanged by the kidneys. In type
2 diabetes patients and patients with moderate-to-severe
CKD, dose reductions for vildagliptin are required, which
means a reduction by half (to 50 mg/day) for both moderate
and severe CKD (31-33). Saxagliptin is metabolized, mainly
in the liver, into an active metabolite that is eliminated in the
urine. The normal dose (5 mg once daily) should be reduced
to 2.5 mg once daily in patients with moderate or severe
renal impairment and excluded for patients with ESRD
requiring hemodialysis (34). Meanwhile, linagliptin is the
only DPP-4 inhibitor that is eliminated nearly entirely via the
bile, thus making this agent a possible treatment choice for
patients with normal kidney function as well as for patients
in all stages of CKD, and even stage 5 (GFR o15 mL/min/
1.73 m2), without dose adjustments (35). Alogliptin is
primarily excreted unchanged in the urine and the usual dose
is 25 mg once per day. However, for individuals with a
decreased filtration rate, the dosage should be adjusted.
Therefore, for patients with a creatinine clearance rate between
30 and 60 mL/min, the dose is 1.25 mg per day, whereas for
those with greater loss of renal function or hemodialysis, the
recommended dose is only 6.25 mg/day (36).
The safety of this therapeutic class has been questioned
after the release of a phase 4 trial showing increase in
hospitalization for HF. Certain risk factors are associated
with this higher HF rate, such as previous HF, a GFR of
o60 mL/ min and increased levels of N-terminal pro-B-type
natriuretic peptide (BNP) (37). Moreover, a meta-analysis of
59 randomized controlled trials involving 36,620 patients
treated with DPP-4 inhibitors for at least 24 weeks also
showed a significant increase in the occurrence of HF
compared with the placebo group. Furthermore, a potential
interaction of the therapeutic class of gliptins with other
drugs, such as angiotensin-converting enzyme inhibitors
(ACEIs), BNP, substance P and neuropeptide Y (NPY), has
been suggested (38).
Incretin mimetics
Incretin mimetics include glucagon-like peptide 1 (GLP1)
analogs and agonists (exenatide, lixisenatide and liraglutide),
which increase insulin secretion and suppress glucagon secre-
tion in a glucose-dependent manner, with reduced risk of
hypoglycemia. These mimetics also slow gastric emptying and
suppress appetite via central nervous system modulations,
resulting in a reduced body weight. However, the main side
effects are nausea and vomiting. Exenatide is predominantly
eliminated by glomerular filtration and its clearance is mildly
reduced in patients with mild or moderate renal impairment,
whereas in subjects with ESRD, its removal is significantly
reduced. Lixisenatide is eliminated through glomerular filtra-
tion, followed by tubular reabsorption and subsequent meta-
bolic degradation, resulting in smaller peptides and amino acids
that are introduced into protein metabolism. However, data
from patients with kidney disease are limited. In persons
without diabetes, mild-to-moderate renal impairment did not
appear to affect the drug’s pharmacokinetics or safety, but drug
exposure was increased in persons with severe renal impair-
ment, suggesting the need for dose adjustment in this
population. Finally, liraglutide is metabolized in a manner
similar to that for large proteins and its elimination is not related
to a specific organ. Currently, its prescription in patients beyond
mild-stage renal disease is limited and there are no recommen-
dations that support its use in the moderate and severe stages
(28,39).
Sodium-glucose cotransporter 2 inhibitors
The sodium-glucose cotransporter 2 (SGLT2) protein,
expressed in the kidney proximal tubules, is able to reabsorb
approximately 90% of glucose filtered through the glomeruli.
A new generation of drugs called SGLT2 inhibitors act by
lowering plasma glucose by promoting glycosuria and
osmotic diuresis, thus directly reducing plasma glucose
concentrations in patients with hyperglycemia. This ther-
apeutic class has been approved for the treatment of patients
with T2DM with an eGFR ofX45 mL/min/1.73 m2. To date,
however, just canagliflozin has been evaluated, showing
safety and efficacy in a subset of patients with stage 3 CKD
(40,41).
Table 1 shows a summary correlating the therapeutic class
and the dose adjustment based on creatinine clearance.
Insulin therapy
The kidney also plays an important role in insulin
clearance from the systemic circulation by distinct pathways.
The first route involves glomerular filtration and subsequent
absorption of insulin by proximal tubular cells through
endocytosis. The second includes insulin diffusion through
the peritubular capillaries and its binding to the contral-
uminal tubular membrane of cells and especially those
located in the distal half of the nephron. As a result, insulin is
transported by lysosomes and is metabolized into amino
acids that are released into the peritubular vessels by
diffusion, after which the final degradation products are
reabsorbed (43,44). As exogenous insulin does not undergo a
first-pass effect in the liver, the kidney plays an important
role in removing insulin and is thus crucial to the metabolism
and clearance of insulin in patients with renal impairment.
CKD is associated with several disorders of insulin and
carbohydrate metabolism and when renal failure advances,
insulin clearance decreases, demanding a dose reduction to
prevent hypoglycemia. This reduction in insulin clearance is
initially compensated for an increase in insulin uptake by
proximal tubular cells, and it is also associated with an
increase in insulin resistance (45,46).
Few studies have examined the pharmacokinetics of long-
acting insulin in diabetic patients with CKD. Although
patients with impaired kidney function have lower insulin
requirements, no dose adjustment is required if the GFR is
450 mL/min (45,47,48). Therefore, certain authors have
suggested an insulin reduction to 75% of the total daily dose
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when the GFR is between 10 and 50 mL/min and to 50% for
a GFR of o10 mL/min, independent of the insulin type
being used (49).
Neutral protamine Hagedorn insulin (NPH) is known as
an intermediate-acting insulin. Its time-action profile shows a
typical peak within 4–7 hours after subcutaneous injection,
and it is usually administered twice or three times daily (27).
Insulin analogs, which are produced by recombinant DNA
technology, could be short acting (lispro, aspart or glulisine
insulin) or could be long- or ultra-long-acting basal insulin
analogs (glargine, detemir and degludec). Used together,
these analogs can simulate physiological insulin profiles
more closely than regular and NPH insulin can (27,48).
Because of its pharmacokinetics and stable half-life, insulin
glargine has a time-action profile of approximately 24 hours
and should be prescribed as a once-daily medication (50).
However, few studies have been published on the use of
glargine insulin in patients with impaired renal function. One
of these studies enrolled 89 patients with diabetes and a renal
clearance of 34.1±11.5 mL/min who were treated with oral
antidiabetic drugs or NPH insulin, although with sub-optimal
glycemic control or frequent hypoglycemic episodes. Insulin
treatment was then switched to insulin glargine at bedtime,
with the addition of regular insulin to reach 100–140 mg/dL
preprandial blood glucose. There was an improvement
in glycemic control observed, based on the rapid decline in
A1C (8.4±1.6% (68±4.5 mmol/mol) and 7.7±1.2% (61±5.3
mmol/mol) at baseline and after 4 months, respectively),
showing safety and good tolerance for glargine insulin added
to regular insulin in type 2 diabetes patients with diabetic
nephropathy (51).
Another long-acting insulin analog that is commercially
available is insulin detemir, which has an onset of action of
1 hour and a time-action profile of 12–24 hours, and, depending
on patients’ sensibility, it can be administered once daily
(52,53). Kulozik and Hasslacher (48) showed that reduction in
the GFR was associated with a lower dosage of two long-acting
insulins (glargine and detemir). In other words, the insulin
dosage at a GFR ofo60 mL/min was 29.7% lower in glargine-
treated patients and 27.3% lower in detemir-treated patients
Table 1 - Relationship among therapeutic class, medication dose and creatinine clearance.
Class and Medication Dose Adjustment Based on eGFR
Biguanide
Metformin USA prescribing information: contraindication for men with serum creatinine X1.5 mg/dL and women with serum
creatinine X1.4 mg/dL
UK guideline allows metformin in patients with eGFR 430 mL/min/1.73 m2
KDIGO recommends metformin in patients with eGFR 445 mL/min/1.73 m2
Sulfonylureas
Glipizide No dose adjustment required
Glimepiride Initiate conservatively at 1 mg daily
Avoid use if eGFR o60 mL/min/1.73 m2
Gliclazide Reduce dose if eGFR o30 mL/min/1.73 m2. Not recommended if eGFR o15 mL/min/1.73 m2
Glyburide or glibenclamide Avoid use in patients with eGFR o60 mL/min/1.73 m2
Meglitinides
Repaglinide Initial dose of 0.5 mg before meals when eGFR o30 mL/min/1.73 m2
Nateglinide Caution when used with eGFR o30 mL/min/1.73 m2. Initiate with 60 mg before meals
a-Glucosidase inhibitors
Acarbose Avoid if eGFR o30 mL/min/1.73 m2
Miglitol Avoid if eGFR o30 mL/min/1.73 m2
TZDs
Pioglitazone No dose adjustment required. Use with caution in patients with CKD and hypervolemia
GLP-1 receptor agonists
Exenatide Avoid if eGFR o30 mL/min/1.73 m2. When eGFR between 30 and 50 mL/min/1.73 m2 dose should not exceed 5 mcg
Lixisenatide Avoid if eGFR o50 mL/min/1.73 m2
Liraglutide Avoid if eGFR o60 mL/min/1.73 m2
DPP-4 inhibitors Sitagliptin and saxagliptin dose adjustment required based on eGFR
Sitagliptin 100 mg daily if eGFR o50 mL/min/1.73 m2
50 mg daily if eGFR 30–50 mL/min/1.73 m2
25 mg daily if eGFR o30 mL/min/1.73 m2
Saxagliptin 5 mg daily if eGFR o50 mL/min/1.73 m2
2.5 mg daily if eGFR o50 mL/min/1.73 m2
Alogliptin 1.25 mg per day when eGFR 30–60 mL/min/1.73 m2, and for those patients with eGFR o30 mL/min/1.73 m2 or
hemodialysis, the dose should not exceed 6.25 mg/day
Linagliptin No dose adjustment required
SGLT2 inhibitors
Canagliflozin No dose adjustment required if eGFR o60 mL/min/1.73 m2
100 mg daily if eGFR 45–59 mL/min/1.73 m2
Dapagliflozin Avoid use if eGFR o60 mL/min/1.73 m2, and discontinue use if eGFR o45 mL/min/1.73 m2
Legend: USA: United State of America; UK: United Kingdom; KDIGO: Kidney Disease Improving Global Outcomes; eGFR: estimated glomerular filtration rate;
TZDs: thiazolidinediones; GLP-1 receptor agonists: glucagon-like peptide-1 receptor agonists; DPP-4 inhibitors: dipeptidyl peptidase 4 (DPP-4) inhibitors; SGLT2
inhibitors: sodium- glucose cotransporter 2 (SGLT2) inhibitors.
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compared with the dosage at an eGFR of490 mL/min. These
authors did not find any difference between insulin detemir
and insulin glargine with respect to sodium, albumin, or
protein excretion in patients with type 2 diabetes and CKD.
A new-generation basal insulin with an ultra-long
duration of action, insulin degludec, was approved to be
commercialized, but there has been just one study in patients
with different GFRs (54). This study evaluated thirty subjects
with normal renal function; mild, moderate or severe renal
impairment; or ESRD following a single subcutaneous dose
of insulin degludec. No statistically significant differences in
absorption or clearance, compared with subjects with normal
renal function, were observed up to 120 hours post-dose,
even in those with ESRD, regardless of whether the
pharmacokinetic assessment period included hemodialysis.
Based on this study, dose adjustments due to impaired renal
function should not be required for insulin degludec (54).
Insulin lispro, insulin aspart and insulin glulisine are short-
acting insulin analogs with very similar pharmacokinetic profiles.
They are present either in monomeric or in very weakly bound
hexameric forms, which are rapidly absorbed following sub-
cutaneous injection. These insulin analogs usually reach their
plasmatic concentration after approximately 60–90 minutes and
have a duration of action of 3–4 hours (55). As insulin lispro was
the first analog investigated, there have been several studies in
patients with CKD (56-58). In type 2 diabetes patients with overt
nephropathy, lispro insulin prevents glomerular hyperfiltration
and reduces the renal effects of meal-associated hyperglycemia
by mechanisms possibly related to insulin-like growth factor 1
(IGF-1) antagonism (56). Studies in a diabetic population with
end stage renal disease undergoing hemodialysis treatment
suggested that this analog can provide better glycemic control
and improve quality of life (57,58). Insulin glulisine was also
effective and safe in suppressing postprandial hyperglycemia in
type 2 diabetes patients with severe renal insufficiency (59).
Moreover, renal impairment does not affect the pharmacokinetics
of insulin analogs in a clinically significant manner, as demon-
strated for insulin aspart (60).
The search for the combination of keywords related to short-
and long-acting insulin analogs yielded a few studies in
patients with renal insufficiency. However, one study that
enrolled hospitalized patients with the objective of evaluating
insulin doses and hypoglycemia frequency showed that after
initial reduction of glargine/glulisine insulin weight-based
dosing, there was a notable decline in hypoglycemic events,
or a 50% reduction, without compromising glycemic control
(61). Regardless of the insulin considered as the best choice to
improve glycemic control in patients with renal failure, specific
information about dose adjustment and differences in insulin
profiles in this population is still missing.
Glycemic control in patients with diabetic
kidney disease
Intensive glucose control decreases the risk of microalbumi-
nuria and macroalbuminuria, but evidence is lacking as to
whether intensive glycemic control reduces the risk of clinically
significant renal outcomes, such as doubling of creatinine,
ESRD or death from renal disease during the years of follow-up
(61). Many have tried to explain the controversy about the
beneficial effect of tight glycemic control on clinically important
renal endpoints. It appears difficult to undo both the changes
secondary to a long-lasting high mean glucose level and the
long-term effects on the development and progression of
diabetes complications, even if tight glycemic control is
maintained for many years afterward. A phenomenon known
as ‘‘metabolic memory’’ or the ‘‘legacy effect’’ may be involved,
including epigenetic programming, compositional changes,
post-translational modifications, or simply lead time toward
an inevitable fate (62).
Despite efforts to prevent morbidity and mortality in diabetes
through guidelines and recommendations, a significant portion
of the diabetic population still does not receive adequate care, as
described by several reports auditing the quality of care (63,64).
These studies’ results demonstrate that adherence to guidelines
is associated with better outcomes among patients with diabetes.
However, adherence to practice guidelines is still low, especially
regarding checking capillary blood glucose; performing eye
examinations; achieving targets for blood pressure, A1C and
low-density lipoprotein (LDL) cholesterol; and prescribing
ACEIs and angiotensin II receptor blockers (ARBs), antiplatelet
agents and statins. To address these controversies, the Standards
of Medical Care in Diabetes 2014 of the American Diabetes
Association (ADA) (8), the Kidney Disease: Improving Global
Outcomes (KDIGO) 2012 guidelines (65), and the Clinical Practice
Guidelines for the Evaluation and Management of Chronic
Kidney Disease and the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (KDOQI) guidelines for the
management of diabetes with CKD (7) recommend a target A1C
ofo7.0% to prevent or retard the progression of CKD. Still, none
of these guidelines defines the goals for glycemic control in
patients with renal impairment and a GFR of o45 mL/min.
In addition, several studies have questioned the accuracy of A1C
as a reliable marker of the blood glycemic average, and extreme
values for A1C, whether below 6% (42 mmol/mol) or above 9%
(72 mmol/mol), have been correlated with the worst prognosis
in individuals with significant loss of renal function (65,66).
The individualization of therapy, taking into account factors
such as the presence of complications and other diseases, disease
management capabilities, the CKD stage, the duration of disease,
and previous glycemic control, among other factors, should be
evaluated and may be considered as a safe and effective strategy
for these patients (67-69). Therefore, a multidisciplinary team,
including nephrologists, endocrinologists, dietitians and nurses,
is important to help to identify individualized targets in patients
with diabetic nephropathy. The health team is specifically
responsible for supporting and motivating patients to follow a
specific diet for diabetes control and renal protection, in addition
to providing themwith both orientation for exercise practice and
explanations of the benefits of complying with the instructions,
which is essential to prevent renal complications and/or to slow
the progression of loss of kidney function.
The management of hyperglycemia in patients with DKD is
even more difficult as a result of reduced glomerular filtration
and its interference with glucose metabolism in many ways,
favoring both hyperglycemic peaks and hypoglycemia. Addi-
tionally, renal failure impairs the clearance and metabolism of
antidiabetic agents and insulin, thus frequently necessitating
reassessment of prescriptions or adjustment of doses (48,70).
Physicians responsible for the follow-up of these patients should
be vigilant and prepared to make such changes; however,
unfortunately, there are few guidelines addressing the nuances of
the management of this specific population.
The dilemma of treating hyperglycemia in advanced
kidney disease is how to balance tight glycemic control
and harmful effects on the patient’s safety. In other words,
keeping glycemia within the normal narrow range to reduce
the progression of the disease, improving quality of life, and
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minimizing comorbidities should be balanced, especially to
avoid hypoglycemia, which is associated with increased
cardiovascular risks. However, to date, the real benefits and
impact of tight glycemic control in patients with long-
standing diabetes and advanced CKD in particular are not
yet fully known.
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